Alterity Therapeutics Limited
NASDAQ:ATHEBiotechnology
+$0.53 today
- Market cap
- $52.77M
- Beta
- -0.03
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$0.07
Volume 0.02M
Average 0.05M
ATHE Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Alterity Therapeutics LimitedNASDAQ: ATHE
Operating Margin · Q2 FY2026 · quarter ended Dec 2025
Operating margin not reported for Q2 FY2026
Over 3 fiscal years it widened by 34.6 pp.
Context
- Operating margin widened in 1 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 6 analysts of -321.1% for the fiscal year ending Jun 2026, down from -268.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- —— QoQ
- Last fiscal yearJun 2025
- -268.0%+219.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +219.7 pp | -53.2 pp | -272.9 pp |
| 3 years | +34.6 pp | +94.6 pp | +60.0 pp |
| 5 years | +237.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -268.0%
- Year-over-year change
- +219.7pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | -268.0% | +219.7pp |
| FY2024 | 2024-06-30 | -487.7% | -114.0pp |
| FY2023 | 2023-06-30 | -373.7% | -71.2pp |
| FY2022 | 2022-06-30 | -302.6% | +47.2pp |
| FY2021 | 2021-06-30 | -349.8% | — |
Operating Margin vs competitors
How ATHE compares with its peers on the latest reported figures
- ATHE's FY2025 operating margin of -268.0% is the lowest of the 2 companies compared; the peer median is -238.4%.
- Its year-over-year change of +219.7 pp is the highest of 2, against a peer median of -65.6 pp.
- Over three fiscal years its change of +34.6 pp compares with a peer median of -233.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -238.4% | -65.6 pp | -233.0 pp | |
| FY2025 | -268.0% | +219.7 pp | +34.6 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ATHE) | -238.4% | -65.6 pp | -233.0 pp | |
Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 4.34M | 5.12M | 3.92M | 4.02M | 5.44M |
| Cost of Revenue | 360.03K | 364.67K | 285.07K | 214.3K | 127.52K |
| Gross Profit | 3.98M | 4.76M | 3.63M | 3.8M | 5.31M |
| Gross Margin | 91.7% | 92.9% | 92.7% | 94.7% | 97.7% |
| Research & Development | 12.28M | 14.75M | 13.2M | 18.64M | 14.4M |
| Selling, General & Admin | 6.87M | 5.51M | 5.04M | 4.76M | 5.48M |
| Operating Expenses | 19.16M | 20.26M | 18.24M | 23.41M | 19.89M |
| Depreciation & Amortization | 18.66K | 54.21K | 37.85K | 35.34K | 28.31K |
| EBITDA | (15.16M) | (17.39M) | (14.6M) | (19.57M) | (14.63M) |
| EBITDA Margin | -349.3% | -339.5% | -372.8% | -486.9% | -269.0% |
| Operating Income | (15.18M) | (15.5M) | (14.64M) | (19.6M) | (14.57M) |
| Operating Margin | -349.8% | -302.6% | -373.7% | -487.7% | -268.0% |
| Interest Income | 20.68K | 2.5K | 16.44K | 268.42K | 446.29K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (133.04K) | 2.72M | 904.68K | 524.33K | 2.49M |
| Income Before Tax | (15.31M) | (12.78M) | (13.7M) | (19.08M) | (12.08M) |
| Pre-Tax Margin | -352.8% | -249.4% | -349.9% | -474.6% | -222.1% |
| Income Tax Expense | (3.08M) | 70.01K | 104.46K | 46.09K | 68.06K |
| Net Income | (15.31M) | (12.85M) | (13.81M) | (19.12M) | (12.15M) |
| Net Margin | -352.8% | -250.7% | -352.5% | -475.8% | -223.4% |
| EPS (Basic) | (5.40) | (3.18) | (3.42) | (3.12) | (1.14) |
| EPS (Diluted) | (5.40) | (3.18) | (3.42) | (3.12) | (1.14) |
| Weighted Avg Shares | 2.83M | 4.01M | 4.05M | 6.08M | 10.66M |
| Weighted Avg Shares (Diluted) | 2.83M | 4.01M | 4.05M | 6.08M | 10.66M |
Alterity Therapeutics Limited
NASDAQ:ATHE
Intrinsic Alpha fair value
Locked
Current Price
$3.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.